Companies Dominating the Enzyme Replacement Therapy Landscape
- BioMarin
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Leadiant Biosciences, Inc.
- Pfizer Inc.
- Sanofi Aventis
- AbbVie Inc.
- Takeda Pharmaceutical Company Limited
- JCR Pharmaceutical Co., Ltd.
- AstraZeneca plc
- Clinigen Limited
- Teijin Limited
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Enzyme Replacement Therapy Market in 2025 is evaluated at USD 12.06 billion.
The global market size was worth more than USD 11.42 billion in 2024 and is poised to witness a CAGR of over 7%, crossing USD 27.52 billion revenue by 2037.
Asia Pacific is likely to achieve majority share by 2037, driven by growing patient population with rare disorders, rising disposable income, and increased healthcare sector growth.
The major players in the market include BioMarin, Leadiant Biosciences, Inc., Pfizer Inc., Sanofi Aventis, AbbVie Inc., Takeda Pharmaceutical Company Limited, JCR Pharmaceutical Co., Ltd., AstraZeneca plc, Clinigen Limited, Teijin Limited.
